Cleveland Biolabs Inc. Daily Stock Analysis

Daily Stock Analysis, CBLI, Cleveland Biolabs Inc, priceseries

Cleveland Biolabs Inc. Daily Stock Analysis
Stock Information
Open
3.81
Close
3.64
High
3.81
Low
3.46
Previous Close
3.82
Daily Price Gain
-0.18
YTD High
192.00
YTD High Date
Mar 15, 2011
YTD Low
0.50
YTD Low Date
Nov 25, 2019
YTD Price Change
-66.36
YTD Gain
-94.80%
52 Week High
7.17
52 Week High Date
Apr 13, 2021
52 Week Low
2.11
52 Week Low Date
Oct 8, 2021
52 Week Price Change
-1.85
52 Week Gain
-33.70%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 19. 2017
3.43
May 25. 2017
3.61
4 Trading Days
5.17%
Link
LONG
Sep 18. 2017
3.04
Sep 28. 2017
3.26
8 Trading Days
7.23%
Link
LONG
Dec 8. 2017
2.66
Jan 12. 2018
3.91
23 Trading Days
46.84%
Link
LONG
Jul 26. 2018
2.46
Jul 31. 2018
2.81
3 Trading Days
14.33%
Link
LONG
Sep 25. 2019
1.10
Sep 26. 2019
1.17
1 Trading Days
6.36%
Link
LONG
Jan 23. 2020
1.09
Feb 4. 2020
2.32
8 Trading Days
112.37%
Link
LONG
Feb 24. 2020
2.27
Mar 2. 2020
2.60
5 Trading Days
14.65%
Link
LONG
Oct 5. 2020
2.06
Oct 26. 2020
2.55
15 Trading Days
23.92%
Link
LONG
Nov 3. 2020
2.82
Nov 17. 2020
2.99
10 Trading Days
6.12%
Link
LONG
Jan 25. 2021
4.33
Feb 19. 2021
7.38
18 Trading Days
70.55%
Link
LONG
Oct 11. 2021
2.57
Oct 27. 2021
3.32
12 Trading Days
29.19%
Link
Company Information
Stock Symbol
CBLI
Exchange
NasdaqCM
Company URL
http://www.cbiolabs.com
Company Phone
(716) 849-6810
CEO
Yakov Kogan
Headquarters
New York
Business Address
73 HIGH STREET, BUFFALO, NY 14203
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001318641
About

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company, with a focus on oncology and acute radiation syndrome drug development. It is engaged in the research, development and commercialization of products that have the potential to treat cancer which reduces death from total body irradiation and counteract the toxic effects of radio and chemotherapies for oncology patients. The company has designed two oppositely-directed general therapeutic concepts: temporary and reversible suppression of apoptosis in normal cells to protect healthy tissues from stress-induced damage using compounds categorized as Protectans; and reactivation of apoptosis in tumor cells to eliminate cancer using compounds categorized as Curaxins. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Buffalo, NY.

Description

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The company's advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading